Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Lobato Fuertes

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Orphanet Journal of Rare Diseases|February 24, 2024
Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1Ana M Cieza Rivera, Carlos Lobato Fuertes, Tania Fernández-Villa, et al.
Ophthalmology|August 5, 2009
Adalimumab for Mooren's ulcerMiguel Cordero-Coma, Manuel Franco Benito, Carlos Lobato Fuertes, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Orphanet Journal of Rare Diseases|February 24, 2024
Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1Ana M Cieza Rivera, Carlos Lobato Fuertes, Tania Fernández-Villa, et al.
Ophthalmology|August 5, 2009
Adalimumab for Mooren's ulcerMiguel Cordero-Coma, Manuel Franco Benito, Carlos Lobato Fuertes, et al.
Pageof 1